AbbVie Inc, Common Stock






Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
Volume info-icon
This is the total number of shares traded during the most recent trading day.
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$127.03 L
$179.89 H

About AbbVie Inc, Common Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate t...more

Industry: BiotechnologySector: Health Care


Time FrameABBVSectorS&P500
1-Week Return0.46%-2.06%0.03%
1-Month Return6.75%1.84%3.84%
3-Month Return25.95%10.35%11.14%
6-Month Return23.1%9.35%13.49%
1-Year Return19.89%15.97%30.78%
3-Year Return86.55%33%36.58%
5-Year Return181.36%69.86%97.17%
10-Year Return438.9%188.37%231.4%


Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue33.27B45.80B56.20B58.05B54.32B[{"date":"2019-12-31","value":57.3,"profit":true},{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true}]
Cost of Revenue7.44B15.39B17.45B17.41B8.78B[{"date":"2019-12-31","value":42.64,"profit":true},{"date":"2020-12-31","value":88.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":50.33,"profit":true}]
Gross Profit25.83B30.42B38.75B40.64B45.54B[{"date":"2019-12-31","value":56.72,"profit":true},{"date":"2020-12-31","value":66.79,"profit":true},{"date":"2021-12-31","value":85.1,"profit":true},{"date":"2022-12-31","value":89.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin77.64%66.41%68.96%70.00%83.84%[{"date":"2019-12-31","value":92.61,"profit":true},{"date":"2020-12-31","value":79.21,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":83.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses12.46B17.86B19.86B21.83B28.11B[{"date":"2019-12-31","value":44.32,"profit":true},{"date":"2020-12-31","value":63.52,"profit":true},{"date":"2021-12-31","value":70.66,"profit":true},{"date":"2022-12-31","value":77.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income12.98B476.00M17.92B18.12B17.43B[{"date":"2019-12-31","value":71.66,"profit":true},{"date":"2020-12-31","value":2.63,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.18,"profit":true}]
Total Non-Operating Income/Expense(6.07B)642.00M(5.90B)(5.34B)(12.86B)[{"date":"2019-12-31","value":-944.86,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-918.54,"profit":false},{"date":"2022-12-31","value":-831.31,"profit":false},{"date":"2023-12-31","value":-2002.96,"profit":false}]
Pre-Tax Income8.43B3.40B12.99B13.48B6.25B[{"date":"2019-12-31","value":62.52,"profit":true},{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true}]
Income Taxes544.00M(1.22B)1.44B1.63B1.38B[{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":-75,"profit":false},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true}]
Income After Taxes7.88B4.62B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Continuous Operations7.88B4.62B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income7.88B4.62B11.54B11.84B4.86B[{"date":"2019-12-31","value":66.59,"profit":true},{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true}]
EPS (Diluted)8.9410.5112.6813.8711.11[{"date":"2019-12-31","value":64.46,"profit":true},{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true}]



These ratios help you determine the liquidity of the company. Higher is better.

Cash Ratio 0.34
Current Ratio 0.87
Quick Ratio 0.76

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ROA (LTM) 8.07%
ROE (LTM) 35.20%


These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

Debt Ratio Lower is generally better. Negative is bad. 0.92
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.08
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 13.00


These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

Trailing PE 64.94
Forward PE 15.75
P/S (TTM) 5.74
P/B 30.35
Price/FCF 69
EV/R 6.65
EV/Ebitda 21.02


AbbVie Inc (ABBV) PRES & CHIEF OPERATING OFFICER Robert Michael Sells 68,879 Shares

AbbVie Inc (ABBV) PRES & CHIEF OPERATING OFFICER Robert Michael Sells 68,879 Shares

2 Mar, 2024 a 4:35 am GuruFocus

Abbvie Inc To Acquire Cerevel Therapeutics Transcript

Abbvie Inc To Acquire Cerevel Therapeutics Transcript

2 Mar, 2024 a 1:26 am GuruFocus

The Hot List: 3 AI Stocks Worth Buying on Weakness

Wall Street has correctly recognized that artificial intelligence ( AI ) is a game-changer. It enables individuals to use computers more easily than ever before to find the best answers to complex questions. Additionally, AI allows companies to become more productive and profitable by reducing their labor costs. This is because AI can perform some tasks once carried out by humans. However, Wall Street has mostly focused on buying into firms that sell the tools needed to produce or utilize AI. Further, the Street has ignored the companies that use the technology to improve businesses in fields like healthcare and finance. So, the shares of many firms will eventually climb significantly because they’ve spent years building highly potent AI tools. As a result, their products will yield superb results for their customers, causing the demand for their offerings to surge. So, let’s delve into three such AI stocks . Schrodinger ( SDGR ) Source: Olga Kononok/Shutterstock Schrodinger (NASDAQ: SDGR ) uses physics and AI technology to speed up the drug discovery process.

1 Mar, 2024 a 12:30 pm InvestorPlace

Blue-Chip Backbone: 3 Stocks for Unwavering Market Strength

It’s often said that patience is a virtue for investors that often means taking advantage of the stability of blue-chip stocks . However, that virtue can be sorely lacking among investors. In good times, investors are frequently drawn to the next shiny object. And when growth is hard to come by, they can move into more speculative assets, seeking growth at all costs. But history says investors with a long-term focus can still do better looking at solid blue-chip stocks. These stocks frequently are in defensive sectors. However, many of these companies do a pretty good job of playing both offense and defense. That’s the case with the three stocks listed here. They all have some compelling defensive qualities, including rock-solid dividends. Each offers products and services that are generally in demand regardless of the state of the economy. And over time, each of these companies has delivered a strong total return for investors. AbbVie (ABBV) Source: Valeriya Zankovych / AbbVie (NYSE: ABBV ) is one of the top blue-chip stocks for long-term investors.

29 Feb, 2024 a 10:50 pm InvestorPlace

Better Dividend Growth Stock: AbbVie or Amgen?

A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy.

29 Feb, 2024 a 2:45 pm The Motley Fool

OSE Immunotherapeutics - Confidence boost with AbbVie partnership

OSE Immunotherapeutics has announced a global licence and collaboration agreement with AbbVie to develop OSE-230, a novel monoclonal antibody, for the treatment of chronic and severe inflammation. …

28 Feb, 2024 a 2:34 pm Finanz Nachrichten

OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), will host a live webcast on February 28, 2024, at 6:00 p.m. CET to discuss the global collaboration and license agreement with AbbVie and outline the Company’s strategic focus moving forward. The live webcast will be available at the following link: WEBCAST Jetzt den vollständigen Artikel lesen

28 Feb, 2024 a 6:45 am Wallstreet:Online

AbbVie To Receive Global License To Develop OSE-230 From OSE Immunotherapeutics

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AbbVie Inc. (ABBV) and OSE Immunotherapeutics SA announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and se…

28 Feb, 2024 a 5:54 am Finanz Nachrichten


What is AbbVie Inc share price today?

AbbVie Inc (ABBV) share price today is $178.91

Can Indians buy AbbVie Inc shares?

Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AbbVie Inc be purchased?

Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.

How to invest in AbbVie Inc shares from India?

You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABBV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AbbVie Inc shares
What is AbbVie Inc 52-week high and low stock price?

The 52-week high price of AbbVie Inc (ABBV) is 179.89. The 52-week low price of AbbVie Inc (ABBV) is 127.03.

What is AbbVie Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 65.78

What is AbbVie Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 30.35

What is AbbVie Inc dividend yield?

The dividend yield of AbbVie Inc (ABBV) is 3.48%

What is the Market Cap of AbbVie Inc?

The market capitalization of AbbVie Inc (ABBV) is $316.04B

What is AbbVie Inc’s stock symbol?

The stock symbol (or ticker) of AbbVie Inc is ABBV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top